Immune checkpoint inhibitors (ICIs) against PD-1 and PD-L1, or the first-line treatment drugs for other ovarian cancers like anti-angiogenic drugs such as vascular endothelial growth factor (VEGF) inhibitors and tyrosine kinase inhibitors (TKI) are also promising therapies for SCCOPT: in a study published in 2022, the authors described a two-year survival following surgery and no recurrence during follow-up in a patient with brain metastases from SCCOPT treated simultaneously with apatinib (TKI) and carilizumab (PD1 antibody) [3]. This evidence concerns the gene VEGFA and ovarian cancer.